Sacubitril/Valsartan as a New Possible Therapeutic Alternative for the Treatment of Hypertension
Published: 2023-12-30
Page: 437-441
Issue: 2023 - Volume 6 [Issue 1]
Anish Desai
IntelliMed Healthcare Solutions, Mumbai, India.
Sunaina Anand
IntelliMed Healthcare Solutions, Mumbai, India.
Prachi Sanghvi *
IntelliMed Healthcare Solutions, Mumbai, India.
Aanchal Gvalani
IntelliMed Healthcare Solutions, Mumbai, India.
Priyanka Das
IntelliMed Healthcare Solutions, Mumbai, India.
*Author to whom correspondence should be addressed.
Abstract
Hypertension, a major modifiable risk factor for cardiovascular disease and global mortality, affects approximately 31.1% of adults worldwide. Resistant hypertension, observed in 13-30% of hypertensive patients, poses a challenge in treatment escalation, contributing to clinical inertia. Sacubitril/valsartan, a dual-action compound comprising valsartan (an angiotensin receptor blocker) and sacubitril (a neprilysin inhibitor), has garnered approval in China and Japan for Hypertension and FDA approval for heart failure. This article aims to review the possibility of sacubitril/ valsartan as an alternative therapy for the treatment of hypertension. Clinical evidence indicates sacubitril/valsartan's efficacy in reducing blood pressure. Notably, it also demonstrates significant blood pressure reductions in patients with heart failure, emphasizing its dual benefits. The compound's superior efficacy in improving hypertension and left ventricular hypertrophy is a focus of ongoing investigations. This review highlights the role of sacubitril/valsartan as a promising therapeutic option for the management of hypertension.
Keywords: Blood pressure, hypertension, sacubitril/valsartan
How to Cite
Downloads
References
Stanaway JD, Afshin A, Gakidou E, Lim SS, Abate D, Abate KH, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018; 392(10159):1923–94.
Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018; 392(10159):1736–88.
Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–50.
Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: Detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018; 72(5):e53–90.
Mu L, Mukamal KJ. Treatment intensification for hypertension in US Ambulatory Medical Care. J Am Heart Assoc. 2016;5(10):e004188.
Kario K, Rakugi H, Yarimizu D, Morita Y, Eguchi S, Iekushi K. Twenty‐four‐hour blood pressure‐lowering efficacy of sacubitril/valsartan versus olmesartan in japanese patients with essential hypertension based on nocturnal blood pressure dipping status: A post hoc analysis of data from a randomized, double‐blind multicenter study. Journal of the American Heart Association. 2023; 12(8):e027612.
Sible Alexandra M, Nawarskas, James J, Alajajian David, Anderson Joe R. Sacubitril/Valsartan: A novel cardiovascular combination agent. Cardiology in Review. 2016;24(1):41-47 DOI: 10.1097/CRD.0000000000000093
News-Medical.net [Internet]. What is the Renin-Angiotensin-Aldosterone System? 2020 Available:https://www.news-medical.net/health/What-is-the-Renin-Angiotensin-Aldosterone-System.aspx
[Access on 2023 Dec 22].
Sible AM, Nawarskas JJ, Alajajian D, Anderson JR. Sacubitril/Valsartan: A Novel Cardiovascular Combination Agent. Cardiology in Review. 2016;24(1):41–7.
Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. The Lancet. 2010;375(9722):1255–66.
Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K. Role of neprilysin inhibitor combinations in hypertension: Insights from hypertension and heart failure trials. European Heart Journal. 2015;36(30): 1967–73.
Ito S, Satoh M, Tamaki Y, Gotou H, Charney A, Okino N, et al. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res. 2015; 38(4):269–75.
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine. 2014;371(11):993–1004.
Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. The Lancet. 2012;380(9851):1387–95.
Martins e Pereira G, S. Duarte G, Katerenchuk V, Costa J, David C, Ferreira JJ, et al. Safety and tolerability of sacubitril-valsartan: A systematic review and meta-analysis. Expert Opinion on Drug Safety. 2021;20(5):577–88.
207620s018lbl.pdf [Internet]. Available:https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207620s018lbl.pdf
[Access on 2023 Dec 22].
Cheung DG, Aizenberg D, Gorbunov V, Hafeez K, Chen CW, Zhang J. Efficacy and safety o sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study. The Journal of Clinical Hypertension. 2018;20(1):150–8.
Arora P. Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure [Internet]. clinicaltrials.gov; 2023 Report No.: NCT04971720. Available:https://clinicaltrials.gov/study/NCT0497172 [Access on 2023 Jan 1].
Duraes AR. Anti-Hypertensive Effect of Sacubitril/Valsartan in Resistant Hypertension: Randomized Clinical Trial - The HEVA Study [Internet]. clinicaltrials.gov; Report No.: NCT04637152. 2020 Available:https://clinicaltrials.gov/study/NCT04637152 [Access on 2023 Jan 1].
Wang JG. Prospective comparison of angiotensin receptor neprilysin inhibitor (ARNI) with amlodipine on ventricular remodeling in hypertension and left ventricular hypertrophy. [Internet]. clinicaltrials.gov; 2023 [Report No.: NCT04929600. Available:https://clinicaltrials.gov/study/NCT0492960 [Access on 2023 Jan 1].